JPMorgan Chase (JPM) is a publicly traded Financial Services sector company. As of May 20, 2026, JPM trades at $301.85 with a market cap of $805.81B and a P/E ratio of 14.43. JPM moved +2.16% today. Year to date, JPM is -9.15%; over the trailing twelve months it is +11.64%. Its 52-week range spans $202.16 to $337.25. Analyst consensus is buy with an average price target of $334.36. Rallies surfaces JPM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
JPMorgan Resumes Ratings on 14 Biotechs, Sets $515 Vertex and $420 Alnylam Targets: JPMorgan reinstated ratings and price targets on 14 large-cap biotech firms, projecting December 2026 targets including $515 for Vertex, $420 for Alnylam, $415 for BeOne and $180 for Insmed. Analysts highlighted sustained profitability at Vertex, Alnylam and BeOne, margin expansion, diversification moves at BioMarin and Moderna’s oncology push as catalysts.
| Metric | Value |
|---|---|
| Price | $301.85 |
| Market Cap | $805.81B |
| P/E Ratio | 14.43 |
| EPS | $20.92 |
| Dividend Yield | 1.50% |
| 52-Week High | $337.25 |
| 52-Week Low | $202.16 |
| Volume | 6.40M |
| Avg Volume | 0 |
| Revenue (TTM) | $186.97B |
| Net Income | $58.90B |
| Gross Margin | 0.00% |
17 analysts cover JPM: 0 strong buy, 9 buy, 8 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $334.36.